Health and Medicine
-
September 2, 2021
Using billing codes to count cancers
The billing codes in electronic health records are useful for counting skin cancers over time — an important metric for cancer risk assessment and prevention. -
September 2, 2021
Rheumatoid arthritis drug combined with standard of care may help reduce mortality for hospitalized COVID-19 patients
Hospitalized patients with COVID-19 who received the rheumatoid arthritis drug baricitinib, in combination with the standard of care including corticosteroids, died less often than those receiving only the standard of care, according to a study released this week in The Lancet Respiratory Medicine. -
September 2, 2021
Discovery offers insight for development of cancer therapies targeting mutant p53
Vanderbilt researchers have discovered that aneuploidy (an abnormal number of chromosomes) drives malignant phenotypes in cells expressing mutant p53, a tumor suppressor protein that is mutated in more than half of all human cancers. -
September 2, 2021
Study shows gene-drug interactions are common
When a drug or combination of drugs causes different responses in different people, genetic variation is often at play. Pharmacogenomics, through discovery of genetic risk and use of clinical genotyping, aims to reduce trial-and-error approaches to drug prescribing. -
August 24, 2021
Autoimmunity advance
Vanderbilt researchers have developed a high-throughput screening method to identify and characterize antigen-specific B cells — potential biomarkers for autoimmune disease and targets for new treatments. -
August 23, 2021
Estrogen, depression and menopause
A shift in emotional processing may help women adapt to lower estrogen after menopause —unless they have a history of major depressive disorder, Vanderbilt researchers have found. -
August 20, 2021
COVID-19 antibody ‘cocktail’ discovered at VUMC protects chronically ill: study
A monoclonal antibody cocktail against the COVID-19 virus discovered at Vanderbilt University Medical Center and developed by AstraZeneca reduced the risk of symptoms in a study of immunocompromised and chronically ill adults later exposed to the virus by 77%, the company announced today.